The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusion transcript as adjuvant treatment
Ability to understand and willingness to sign a written informed consent document.
Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-based NGS or RT-PCR
surgical procedures,
radiotherapy,
Pregnant or breastfeeding.
Unwilling or unable to follow the study schedule for any reason.
Concurrent or previous treatment within 14 days in another interventional clinical trial with an investigational anti-cancer treatment.
surgical procedures,